Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study

Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study

Indonesian vaccine producer (PT BIOFARMA), conducted a study to assess the safety and immunogenicity of a new COVID-19 vaccine candidate. This vaccine is based on a recombinant subunit protein platform, with the SARS-CoV-2 receptor-binding domain (RBD) as its target antigen. The study compared the c...

Full description

Saved in:
Bibliographic Details
Main Authors: Yetty Movieta Nency, Rini Sekartini, Angga Wirahmadi, Suzy Maria, Nur Farhanah, Rebriarina Hapsari, Endang Mahati, Nani Maharani, Mulyono Mulyono, Dimas Tri Anantyo, Setyo Gundi Pramudo, Glenn Fernandez Yeremia, Lilis Setyaningsih, Mita Puspita, Rini Mulia Sari
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
COVID-19 vaccine
Indovac
safety
phase-1
immunogenicity
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2501467
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items